Trefoil Therapeutics Partners With Price Vision Group for Patients with Corneal Endothelial Dystrophies
Cornea Transplantation,Price Vision Group
Trefoil Therapeutics Begins First Clinical Trial at Price Vision Group for Patients with Corneal Endothelial Dystrophies SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the treatment of people with corneal endothelial dystrophies (CED), including Fuchs Endothelial Corneal Dystrophy. T
Read More
Descemet’s Stripping Only… a substitute for DMEK? An update to a previous post
Cornea Transplantation,Price Vision Group
This is an update to a post published on 9/25/17. You can find the original post here. Descemet’s Stripping Only…a substitute for DMEK? By Francis W. Price, Jr., MD & Matthew T. Feng, MD We are always looking for better ways to correct the visual difficulties of patients with Fuchs’ dystrophy. In fact, that isLeer Más
Read More
Advancements in Cell Regeneration Not Yet as Reliable as DMEK in Fuchs’ dystrophy
Advancements in Cell Regeneration Not Yet as Reliable as DMEK in Fuchs’ dystrophy By Francis W. Price, Jr., MD & Matthew T. Feng, MD We are always looking for better ways to correct the visual difficulties of patients with Fuchs’ dystrophy. In fact, that is why we helped pioneer the evolution of corneal transplants fromLeer Más
Read More